News related to
First Half

Arjavi Indraneesh China’s carefully constructed Gulf strategy is facing one of its toughest tests as Iran’s confrontation with the United States disrupts energy flows, threatens Arab partners and exposes the limits of Beijing’s influence over Tehran. The immediate pressure point is the Strait of Hormuz, where shipping traffic remains sharply below normal levels after months […]

The article Iran escalation puts China’s Gulf strategy under serious strain appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

During the event, Dato’ Liew Bin, President of the Malaysia Retail Chain Association (MRCA), visited the NINGJI booth. The two parties exchanged views on NINGJI’s brand development, product offerings and expansion plans in the Malaysian market.

Backed by a proven store model and a comprehensive overseas support system, NINGJI attracted strong interest from high-quality investors throughout the event. Over the three-day exhibition, the brand successfully signed agreements for 20 new stores, bringing its total number of contracted stores in Malaysia to 82. Potential partners across multiple regions also expressed interest in establishing strategic partnerships with the brand, demonstrating NINGJI’s growing appeal in international markets.

Through product tastings and immersive interactive experiences, NINGJI also strengthened its connection with local consumers. The event generated several thousand new member registrations, building a valuable base of first-party customer data for future localized marketing initiatives.

As one of China’s leading new-style tea brands, NINGJI began its global expansion at the end of 2024. To date, the brand has signed agreements for more than 150 overseas stores across Malaysia, Singapore, Australia, New Zealand, the United States, Vietnam, Thailand, the Philippines, Indonesia, Cambodia and other markets.

In Malaysia, NINGJI currently operates nine stores, with more than ten additional locations in development. Its network is steadily expanding across key commercial districts, while the brand continues to strengthen its influence throughout Southeast Asia.

Five Localization Strategies for Malaysia, Ningji’s Anchor Overseas Market

With its young and diverse population, well-established food and beverage sector, and year-round tropical climate, Malaysia provides highly favourable conditions for refreshing fresh fruit and lemon tea beverages.

Against this backdrop, NINGJI has identified Malaysia as one of its core overseas markets and is systematically advancing its localization strategy across five key areas: store network development, supply chain infrastructure, product portfolio, organizational capabilities and brand marketing.

Expanding Across Key Commercial Districts and Empowering Every Store Through Digital Intelligence

NINGJI will use Kuala Lumpur and Johor Bahru as two strategic hubs, drawing on its proven store operating experience to establish a more refined system for site evaluation, store development and project management.

The brand has built strong digital capabilities, including an end-to-end digital system covering site selection and daily operations, as well as four AI-powered agents that provide franchise partners with integrated, data-driven support.

While steadily expanding its store network and market coverage, NINGJI remains equally focused on store-level operating quality and long-term profitability. The brand aims to build a high-quality retail network that reaches a diverse range of commercial districts and serves a broad customer base.

Strengthening the Local Supply Chain with a Forward Warehouse in Malaysia

Supply chain capability is the lifeline of any new-style tea brand. In China, NINGJI operates seven warehousing centres, manages more than 2,000 mu of lemon orchards. These capabilities have laid a solid foundation for the brand’s continued expansion.

NINGJI believes that genuine localization means combining the capabilities of its headquarters with local market resources. The brand plans to establish a forward warehouse in Malaysia by the end of the year.

Once operational, the facility will enable efficient “T+1” delivery across Malaysia’s key regions, helping stores reduce the risk of stock shortages while significantly lowering the amount of capital franchise partners need to commit to inventory. It will also provide strong logistical support for the continued expansion of NINGJI’s store network.

Balancing Classics and Innovation to Create Products for Local Tastes

NINGJI’s menu centres on fresh fruit lemon beverages paired with whole-leaf tea. Its use of fresh ingredients and made-to-order hand-shaken preparation gives the brand strong cross-cultural appeal and makes its products naturally suited to international markets.

In Malaysia, NINGJI has chosen not to simply replicate its existing menu. Instead, the brand has adopted a “signature products for customer acquisition plus localized innovation” strategy.

On the one hand, proven bestsellers led by Superior Taste Award-winning YaShiXiang Lemon Tea have launched in Malaysian, on the other hand, NINGJI continues to refine its ingredient transportation and storage solutions while developing products tailored to local flavour preferences and market conditions.

In addition to its consistently popular core products, NINGJI has already launched its new pineapple series in Malaysia. The well-received Lemon Milk Series is scheduled to make its official debut in October.

Moving forward, the brand will maintain a quarterly product launch cycle and continue using localized flavours and product innovation to energize the market.

Establishing a Regional Headquarters and Building a Professional Local Team

Local talent is essential for any brand seeking to establish deep and lasting roots in an overseas market.

NINGJI has already assembled a professional team in Malaysia covering local site selection, store development and operational management, and the team continues to grow. This will further enhance the brand’s responsiveness throughout the entire store development journey, from preliminary site selection and opening preparations to daily operations.

NINGJI also plans to establish a regional headquarters in Malaysia and further strengthen its partner support system across staff training, marketing and operational management.

By working alongside local franchise partners who share its commitment to long-term growth, NINGJI aims to expand the market and create greater opportunities together.

Communicating Across Cultures Through Localized Design and Marketing

NINGJI aims to become part of the everyday lives of Malaysian consumers.

In terms of visual presentation, the brand retains its signature yellow and green colour palette while incorporating local aesthetic preferences. Through its “one store, one design” approach, NINGJI creates open and comfortable social spaces tailored to different locations and communities.

From a marketing perspective, the brand will continue to engage with local festivals and cultural trends while collaborating with Malaysian KOLs and KOCs. By connecting social media content with offline experiences, NINGJI seeks to build an emotional relationship with consumers that goes beyond the products themselves and genuinely become part of the local lifestyle.

During its Kuala Lumpur market launch, for example, NINGJI invited Elyn Leong, a Malaysian member of the girl group Gen1es, to serve as “Store Manager for a Day.” Supported by extensive social media promotion, the “Lemon Tea for the Whole City” campaign generated more than one million views and tens of thousands of user-generated interactions across Xiaohongshu, Instagram and Facebook.

Committed to Long-Term Growth, NINGJI Creates Multidimensional Cultural Dialogue Through Localization

NINGJI believes that true globalization is not about simply replicating an existing model. It is a process of deep integration, continuous learning and ongoing refinement.

The brand continues to adapt its products, operations and communications to the consumer characteristics of each market, moving beyond simply “going global” towards becoming genuinely embedded in local communities.

A representative of NINGJI’s overseas business division said:

“Malaysia has a young, diverse and dynamic consumer market and is an important part of NINGJI’s international growth strategy. In the second half of 2026, while steadily expanding our store network, we will further advance the localization of our products, operations and brand communications. We will also continue strengthening our local team and supply chain infrastructure while building long-term relationships with more partners who understand the Malaysian market.”

Looking ahead, NINGJI will continue to build on its product strength and in-store experience while exploring diverse forms of collaboration with local business organizations, content creators and industry partners.

Starting with a cup of fresh fruit lemon tea, NINGJI aims not only to become part of Malaysian consumers’ everyday lives, but also to work alongside local partners to unlock new growth opportunities in the freshly prepared beverage market.

Hashtag: #NINGJI

The issuer is solely responsible for the content of this announcement.

About NINGJI

NINGJI, a leading new-style tea brand featuring fresh-fruit lemon and original-leaf tea, dedicated to multi-category beverage R&D, digitalized management and operations.

NINGJI opened its first store in Changsha, China, on 8 February 2021. July 2021, the company completed a Series A financing round worth tens of millions of RMB, with investment from ByteDance and Shunwei Capital.

January 2022, NINGJI completed a Series A+ financing round worth hundreds of millions of RMB, led by Tencent, with existing investors also oversubscribing.

Through its distinctive contemporary design and refreshing tea beverages, NINGJI communicates a youthful, flavourful and playful brand philosophy, as well as a more creative and trend-driven approach to everyday life. This positioning has earned recognition and support from consumers across different age groups.

NINGJI began its global expansion at the end of 2024. To date, the brand has signed agreements for more than 150 overseas stores across Malaysia, Singapore, Australia, New Zealand, the United States, Vietnam, Thailand, the Philippines, Indonesia, Cambodia and other markets.

2Q26 Business and Financial Highlights

• Bora delivered historically record-high quarterly revenues of NT$5,889 million in 2Q26, up 47.2% quarter-over-quarter driven by broad-based operational momentum, with basic EPS of NT$4.36.
• CDMO revenue growth and increased site utilization rates, along with strong growth in the rare disease business and a return to growth for generics business of the Pharma Sales operations lifted group profitability, with gross margin expanding to 41.3% from 36.0% and operating margin reaching 16.8% from 10.2% in 1Q26. Excluding one-time costs related to the Weider Global Nutrition transaction, operating margin was approximately 18%.
• CDMO’s strong backlog of US$317 million as of end of 2Q26, another historical high following a strong quarter, signals that Bora’s core business continued to perform with higher demand.
• Pharma Sales’ rare disease franchise continues to show double digit sequential growth and the increased demand from government channels during the quarter with stabilized pricing in DLS has lifted the generics business back to normal.
• Reflecting Bora’s recent increase in investment in Sunway Biotech, from 35.97% to 42.27% and subsequent acquisitions of Weider Global Nutrition’s, the Company has introduced “Consumer Healthcare (CHC)” as a new segment in its revenue mix disclosure beginning this quarter. In 2Q26, revenues from CHC were NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY, and contributed to 14% of the Bora Groups consolidated revenues, an all-time high.
• Cash-on-hand reached an all-time high of NT$8,431 million as the Company was preparing for MacroGenics Inc.’s Rockville facility acquisition.
• The Company has kicked off a group-wide AI in Manufacturing, BORA AIM, program aimed at improving process efficiency across sites, spanning engineering, quality and production. Bora has also signed a partnership with Insilico Medicine for AI drug discovery. The first 6 months will focus on beta version testing of the Bora AIM agents and AI champions to drive process consolidation.
• Share capital increased 0.3% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “We are pleased to announce Bora Group’s return to strong operating profits and double to triple-digit growth on all key margins sequentially, as well as demonstrate that our soft 1Q26 performance was anomalous rather than structural. Our impressive sequential improvement was driven entirely by strong demand from both our CDMO and Pharma Sales businesses, with 2Q26 manufactured batches reaching 0.38 billion doses, led by increased commercial production in Maple Grove and Zhunan sites and a full quarter of operations in the Maryland injectable facility, while our flagship products DLS and VIGAFYDE® in Pharma Sales continues to secure leading market share.

Our focus right now is execution. CAPEX investments in our mature sites, including facilities in Taiwan and in Canada, continue to deliver operational leverage driven by gross margin expansion, and our recently acquired oral solid dose facility in Maple Grove continues to show stellar and impactful demand as we sign more projects. Our 12-month rolling backlog is at historic high in almost all our sites, despite projected manufacturing delays at our Maryland injectable facility as we diligently respond to FDA audit observations from a recent audit. Bora Group’s commitment to the fast-growing Biologics manufacturing industry took another big step as we look to integrate 12,000 liters of capacity, and 3 commercial products from our Rockville facility, as well as see revenue recognition from this acquisition starting Q3. As Bora’s CDMO footprint expands in the US, we continue to capture durable, high-value demand as customers increasingly prioritize supply security and onshore capacity.

In addition, we are seeing sustained growth and improved gross margins in the Vigabatrin franchise, our most important, rare disease franchise, thanks to renegotiations with our partner vendors. Accelerated state and government orders for generics products increased 2Q26 revenues and 6 new generics launches have also supported a more diversified generics portfolio. Together, the advancement in rare disease franchise and generics business has positioned Bora’s Pharma Sales business, operating under the name Upsher-Smith, in a far stronger state than it was just a quarter ago.

As announced in July, we are excited to be developing a group-wide AI in Manufacturing program, BORA AIM, aimed at improving process efficiency across sites, spanning engineering, quality and production. We also announced a partnership with Insilico Medicine to enhance our understanding of AI drug discovery and create more customized AI manufacturing platforms for AIDD small molecules. In the next 12 months, Bora Group will be ready to showcase some exciting AI-enabled CDMO platforms that will truly add value to our partners and sharpen the overall competitive advantages of Bora Group.

As our momentum carries Bora into the second half of the year, we expect margins of our flagship products in Pharma Sales and CHC businesses to hold steady on continuous revenue growth, and improved efficiencies in the CDMO business in addition to consolidation of new revenues from the Rockville facility.”

2Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues increased 30.3% year-over-year and 29.0% quarter-over-quarter including internal orders, and 33.0% and 40.2% external orders only, or NT$2,116.4 million. The growth was primarily driven by a strong rebound in injectables following the semi-annual maintenance in 1Q26 and same period last year, and demand acceleration overall as we continue to meet the increasing backlog.

CDMO business also signed a record high US$378.2 million in total external wins. Highlighted by a 10+2-year, multi product commercial contract in our Maple Grove facility with a new top-20 pharma company, and 14 new molecules from pre-commercial programs from multiple new customers. Bora is confident in its mid- to long-term growth trajectory as pharma and biotech companies continue to look for US based CDMOs as a part of their efforts to onshore US production and improve supply chain resilience.

During the quarter, 0.38 billion doses, or 109 molecules, were developed and manufactured. Contribution from the top 20 global pharmaceutical companies stood at roughly 30% and should increase drastically in the next 8 quarters.

Looking at 3Q26, the Company is highly optimistic, with our backlog having climbed to an unprecedented level even after a strong quarter of manufacturing output. We do anticipate some timing shifts in revenue recognition related to scheduled semi-annual maintenance at our Maryland injectable site, alongside targeted quality-enhancement activities in connection with observations on passive RABS (Restricted Access Barrier System) line received from an FDA audit that took place 2Q26. However, there has been no reduction in total commercial batch productions in 2026 as we speak and several existing clients have initiated transfers to the FlexPro isolator filling lines. RFP activity has risen, with the first GMP PPQ campaign starting in August. On the newest, isolator-based AST lines, factory acceptance testing (FAT) is planned for Q326, with qualification to follow in 2027, expanding our ability to onboard small-scale isolator programs, including tech transfers.

On biologics, Rockville facility revenue recognition started in the first month of 3Q26 and the site has confirmed that it is on track to deliver batch production volumes ahead of last year’s run rate of around 13 batches for the remainder of 2026. We anticipate one-time transaction costs from this acquisition of approximately 3% of the purchase price including legal and FA fee and transition related expenses as stated in the Transition Service Agreement. The Rockville acquisition expands biologics capacity and brings integrated drug substance (DS) and drug product (DP) capabilities under one roof, strengthening our end-to-end service offering and attracting more inbound opportunities and higher value conversion with cross selling opportunities for our injectable business.

For our strategic investment in Tanvex Biopharma, the main Bora Biologics platform company, although the business still operates at a loss, Tanvex has built a strong presence in international conferences, especially Bio International in the US in June. We have seen a positive uptick in pipeline from leading biotechs and heavy weight biopharmas, and stable demand for early-stage PD programs in Zhubei. The Rockville acquisition is expected to orchestrate and accelerate opportunities for Tanvex in the coming quarters.

Pharma Sales Operations

Revenues decreased 2.7% year-over-year and increased 30.4% quarter-over-quarter, arriving at NT$2,934.04 million in 2Q26. The year-over-year decrease was mainly due to a product rationalization program in 2025 that lead to the withdrawal of a basket of legacy generics products.

During the quarter, specialty and brand came in strongly, up 58.8% for the quarter QoQ and displayed almost 50% growth against 2025 run rate. The rare-disease Vigabatrin franchise demand is robust, and our continuous investment in the segment has resulted in much broader patient access compared to when we acquired Upsher-Smith 28 months ago. On coverage, we are on track to achieve year-end formulary goal of >50%, supported by more regional plans and strong physician adoption as they gain experience with VIGAFYDE®. The Company has also renegotiated contracts with suppliers, leading to improved gross margins for the franchise during the quarter and expects full economic contribution starting 3Q26. Simultaneously, the Company out-licensed its non-core assets, Stiripentol generics and 505(b)(2), during the quarter, fully capturing the economic value of these drug assets to enable fueled and renewed focus on core specialty and brand business.

The generics business returned to stability as Upsher-Smith successfully defended flagship product DLS. High value generics advanced 20.6% sequentially from downstream restocking, narrowing the year-to-date YoY decline against 2025 run rate to high teens.

Having executed our way through specialty and brand business growth and generics portfolio optimization, we have returned to the 2023–2024 peaks of Pharma Sales performance but with healthier and more resilient operating profits. As of now, Upsher-Smith sees 6 ANDA pending approval.

CHC Operations

Bora Group has increased holdings of Sunway Biotech to 42.27% through a private placement at $NT 596 million. Subsequently, Sunway completed the acquisition of Weider Global Nutrition (WGN), a global nutritional supplements company with offices in the US, Spain, and Germany and products sold in over 60 countries. Benefitting from the consolidation of WGN that started in May, Consumer Health business totaled NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY. Focusing on longevity and sports nutrition, WGN’s distribution strength is expected to meaningfully contribute to the CHC business in 2026 and beyond and shall deliver vertical-integration synergies to Sunway’s existing ingredients’ manufacturing operations. Together, the WGN acquisition is expected to catapult Sunway Biotech into a leading global nutritional supplements company and substantially accelerate top and bottom-line improvements in the future.

Recent Investor Conference

Bora will host English online earnings call at 8:00 a.m. Taiwan time on Aug. 14^th, 2026. The event will cover the Company’s 2Q26 financial and business results and 2H26 outlook.

English Online Earnings Presentation Link: https://teams.microsoft.com/meet/225504163505748?p=UyyncWl1CnOzjBCNKD

Bora will participate in Goldman Sachs 2026 CDMO day in Singapore in Sept. For 1:1 meetings with management, please contact your GS representative.

Bora 2026 Earnings Schedule

Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraGroup

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

The yuan has gained about 3.6 per cent against the dollar this year, making it one of Asia’s strongest-performing currencies. The advance has persisted despite falling Chinese government bond yields and a widening yield disadvantage against US Treasuries, conditions that would normally encourage capital to favour the dollar. Strong export receipts and increased conversion of dollar earnings by exporters have instead provided sustained support for the currency.

Pressure intensified after the US and Japan intervened to strengthen the yen at the end of July. The operation marked the first coordinated action by Washington and Tokyo to support the Japanese currency since 1998, following a slide that took the yen to four-decade lows. US authorities had also alerted major banks to be prepared for possible intervention through the Federal Reserve Bank of New York, highlighting Washington’s concern about excessive currency volatility.

The yen subsequently surrendered roughly half of its initial gains, but the intervention had broader consequences across Asian foreign-exchange markets. South Korea’s won, the Singapore dollar and the Taiwan dollar have shown relatively high correlations with yen movements, while several other regional currencies have been less sensitive. The spillover has reinforced a wider trend towards appreciation in currencies exposed to North Asian trade and investment flows.

For Beijing, the stronger yuan presents a complicated policy trade-off. Appreciation reduces the local-currency cost of imported commodities and can provide some insulation against inflation generated by energy prices. It can also create more room for monetary easing because policymakers need to worry less about triggering capital outflows or destabilising depreciation.

The cost is greater pressure on exporters at a time when foreign demand has become an increasingly important support for economic activity. China’s export machine has remained resilient while household consumption, property investment and parts of the private economy have struggled to regain momentum. A rising yuan makes Chinese products more expensive abroad and reduces the value of exporters’ overseas earnings when converted back into local currency.

The People’s Bank of China has appeared increasingly willing to moderate the currency’s advance. Daily yuan reference rates have been set weaker than market expectations at times, signalling a preference for slowing appreciation rather than allowing the currency to rise unchecked. China operates a managed exchange-rate system in which the central bank establishes a daily midpoint and permits the onshore yuan to trade within a defined band around that fixing.

The yuan traded around 6.75 per dollar on Wednesday after strengthening through the 6.80 level earlier this year. Exporters have continued selling dollars when the US currency rises, while central-bank guidance has kept the appreciation gradual. Market forecasts generally point towards further controlled yuan strength rather than a rapid revaluation.

The currency’s resilience highlights an unusual divergence inside China’s economy. Long-term sovereign yields have declined as investors price weak domestic demand and subdued inflation, while the yuan has strengthened because of trade surpluses and exporter dollar conversions. China’s current-account surplus has expanded significantly as manufacturing exports have outpaced imports and domestic spending.

That divergence could influence the timing of the next monetary-policy move. One scenario would see the central bank reducing its benchmark policy rate by 10 basis points to 1.3 per cent before the end of the year, using currency strength as protection against depreciation pressure. Expectations remain divided, however, with many economists anticipating unchanged rates through 2026 as policymakers assess inflation, financial stability and the effectiveness of previous easing measures.

July inflation data strengthened the case for additional support. Consumer-price growth slowed to its weakest pace in six months, while producer-price pressures eased, renewing concerns that deflationary forces could return if domestic demand remains subdued. Higher energy costs had previously reduced expectations for further easing.

Currency policy is also becoming more closely tied to trade tensions. China’s expanding manufacturing surplus has generated demands among trading partners for a stronger yuan, particularly as exports of vehicles, machinery, electronics and clean-energy equipment increase. A materially stronger exchange rate would weaken some of that competitive advantage but could also reduce political pressure surrounding trade imbalances.

By K Raveendran Another session of Parliament has closed with an uncomfortable sense of déjà vu. Repeated adjournments, slogan-shouting, demonstrations inside and outside the chambers and legislation moving through amid uproar have again raised the question of whether Parliament is performing the function for which representative democracy created it. The problem is no longer simply […]

The article Parliament Is Losing The Argument To The Smartphone appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

As the first full year following the island-wide special customs operations of the Hainan Free Trade Port (FTP), 2026 has been designated the “Marine Tourism Year,” with a strategic focus on ocean-themed cultural travel. Leveraging policy dividends such as visa-free access for citizens of 86 countries, expanded traffic rights, and offshore duty-free shopping, Hainan has consistently enhanced its openness to the world, fueling a surge in cultural tourism demand. In the first half of this year alone, the island recorded over 1 million inbound visits, a year-on-year increase of 48.8%, underscoring the robust growth momentum of the FTP’s tourism sector.

In Wanning’s Riyue Bay, the international media group experienced firsthand the rapid expansion of Hainan’s coastal sports industry. Renowned as a world-class surfing destination, the bay receives more than 500,000 visits annually, drawing travelers from as far as Australia and Southeast Asia. A major highlight was the nation’s first Olympic-standard artificial surf pool, which employs advanced wave-making technology to simulate 23 different wave types, enabling year-round, all-weather surfing regardless of natural conditions. Mr. Guney Isik Ganimgil, a contributor to Turkey’s Aydınlık newspaper, remarked that Hainan’s cultural tourism development has far exceeded expectations and holds tremendous investment potential.

Eco-empowered tourism and the protection of blue bays are the defining hallmarks of Hainan’s development. The Hainan Ocean Paradise Resort adheres strictly to a policy against capturing wild marine life; its rescue center has successfully rehabilitated and released over 200 rare marine creatures, including sea turtles and hawksbills, back into the wild. Meanwhile, Wuzhizhou Island has pioneered an innovative model of eco-tourism, partnering with universities to develop a tropical marine ranch. Through the strategic deployment of artificial reefs and the transplantation of tens of thousands of coral colonies, the island now offers visitors the opportunity to participate in coral transplantation—a hands-on experience that fosters a virtuous cycle between ecological conservation and tourism engagement, earning high praise from the attending media.

Deepening the integration of culture and tourism has also revitalized Hainan’s traditional maritime heritage. The Danjia fishing rafts continue to enrich their authentic marine-ethnic cultural offerings, continuously diversifying their “product portfolio”. Tianya Town, built around a century-old fishing village, has evolved into a coastal leisure landmark, now home to nearly a hundred boutique homestays and specialty cafés. The Sanya International Duty-Free Shopping Complex, housing over 1,000 international brands, has introduced cutting-edge “duty-free + technology” consumption scenarios. And the Sanya Yacht Tourism Center, with a complete industrial chain, recorded over 220,000 yacht outings in 2025, cementing its status as a premier destination for high-end coastal tourism.

After four days of in-depth exploration, the media delegation witnessed a Hainan that is open, green, and vibrantly dynamic. Today’s Hainan FTP has transcended the traditional model of seaside tourism, with policy as its backbone, ecology as its canvas, and culture as its soul. By continually energizing the blue economy, Hainan is presenting a compelling new vision of high-quality development to the world.

Hashtag: #HainanFreeTradePort

The issuer is solely responsible for the content of this announcement.